Casting-type calcifications on the mammogram suggest a higher probability of early relapse and death among high-risk breast cancer patients

References

• Van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncologist 2005; 10: 30–4
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–74
   PubMed Web of Science ®Google Scholar
• Tabar L, Chen H, Duffy SW, Yen MF, Chiang CF, Dean PB, et al. A novel method for prediction of long-term outcome of women with T1a, T1b and 10–14 mm invasive breast cancers: A prospective study. Lancet 2000; 355: 429–33
   PubMedGoogle Scholar
• Tabar L, Dean PB, Kaufman CS, Duffy SW, Chen HH. A new era in the diagnosis of breast cancer. Surg Oncol Clinics NA 2000; 9: 233–77
   PubMedGoogle Scholar
• Tabar L, Tony Chen HH, Amy Yen MF, Tot T, Tung TH, Chen LS, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1–14-mm invasive breast carcinoma. Cancer 2004; 101: 1745–59
   PubMedGoogle Scholar
• Thurfjell E, Thurfjell MG, Lindgren A. Mammographic finding as predictor of survival in 1–9 mm invasive breast cancers. Worse prognosis for cases presenting as calcifications alone. Breast Cancer Res Treat 2001; 67: 177–80
   PubMedGoogle Scholar
• Zunzunegui RG, Chung MA, Oruwari J, Golding D, Marchant DJ, Cady B. Casting-type calcifications with invasion and high-grade ductal carcinoma in situ. Arch Surg 2003; 138: 537–40
   PubMedGoogle Scholar
• Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817–26
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Webster LR, Bilous AM, Willis L, Byth K, Burgemeister FC, Salisbury EL, et al. Histopathologic indicators of breast cancer biology: Insights from population mammographic screening. Br J Cancer 2005; 92: 1366–71
   PubMedGoogle Scholar
• Peacock C, Given-Wilson RM, Duffy SW. Mammographic casting-type calcification associated with small screen-detected invasive breast cancers: Is this a reliable prognostic indicator?. Clin Radiol 2004; 59: 165–70
   PubMedGoogle Scholar
• Kahan Z, Uhercsak G, Hajnal-Papp R, Boda K, Thurzo L. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer. Oncology 2005; 68: 446–53
   PubMedGoogle Scholar
• Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980–91
   PubMed Web of Science ®Google Scholar
• James JJ, Evans AJ, Pinder SE, Macmillan RD, Wilson AR, Ellis IO. Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?. Clin Radiol 2003; 58: 54–62
   PubMedGoogle Scholar
• Lampejo OT, Barnes DM, Smith P, Millis RR. Evaluation of infiltrating ductal carcinomas with a DCIS component: Correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol 1994; 11: 215–22
   PubMedGoogle Scholar
• Millis RR, Ryder K, Fentiman IS. Ductal in situ component and prognosis in invasive mammary carcinoma. Breast Cancer Res Treat 2004; 84: 197–8
   PubMedGoogle Scholar
• MacMillan RD, Purushotham AD, Cordiner C, Dobson H, Mallon E, George WD. Predicting local recurrence by correlating pre-operative mammographic findings with pathological risk factors in patients with breast cancer. Br J Radiol 1995; 68: 445–9
   PubMedGoogle Scholar
• Malik HZ, Wilkinson L, George WD, Purushotham AD. Preoperative mammographic features predict clinicopathological risk factors for the development of local recurrence in breast cancer. Breast 2000; 9: 329–33
   PubMedGoogle Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract 1]. Breast Cancer Res Treat 2005; 94(Suppl 1)S5
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809–20
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10(Suppl 3)S20–S29
   PubMed Web of Science ®Google Scholar